USPTO Art Unit 1627 Prosecution Statistics

Art Unit Information

Art Unit: 1627
Group: 1620
Tech Center: 1600
Total Cases: 15,057
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
193094482-DIARYLMETHYL-4-AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS AS ANTICANCER, ANTIINFLAMMATORY, ANTIFIBROTIC AND NEUROPROTECTIVE AGENTSAugust 2025November 2025Allow200YesNo
19293960SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONSAugust 2025February 2026Allow601NoNo
19274255TRICYCLIC DERIVATIVES AND RELATED USESJuly 2025January 2026Allow601YesNo
19271410Sapropterin FormulationJuly 2025March 2026Allow811YesNo
19270230Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofJuly 2025December 2025Allow510YesNo
19267357STAT6 MODULATORS AND USES THEREOFJuly 2025February 2026Allow711YesNo
19242785METHOD OF ERADICATING TICKS THAT ATTACH TO HUMANS USING LOTILANER FORMULATIONSJune 2025October 2025Allow410YesNo
19237389PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBJune 2025February 2026Abandon810NoNo
19237465MIRDAMETINIB TREATMENTJune 2025March 2026Abandon910NoNo
192296491,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereofJune 2025September 2025Allow300NoNo
19222062N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USINGMay 2025November 2025Allow610YesNo
19207816STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONEMay 2025September 2025Allow520NoNo
19208416METHODS OF TREATMENT WITH ELINZANETANTMay 2025September 2025Allow510NoNo
19208335METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICSMay 2025July 2025Allow200YesNo
19190493POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOFApril 2025March 2026Allow1121YesNo
19097314COMPOSITIONS FOR THE TREATMENT OF HYPERTENSIONApril 2025August 2025Allow500YesNo
19073585COMPOSITIONS FOR THE TREATMENT OF HYPERTENSIONMarch 2025August 2025Allow510YesNo
19043264METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORSJanuary 2025November 2025Allow920YesNo
19043275METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORSJanuary 2025December 2025Allow1120YesNo
19043303METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORSJanuary 2025December 2025Allow1110NoNo
19038538WRN INHIBITORSJanuary 2025April 2025Allow210NoNo
19038543WRN INHIBITORSJanuary 2025April 2025Allow200YesNo
19030516AMINO ACID COMPOSITIONSJanuary 2025January 2026Allow1230NoNo
19030637AMINO ACID COMPOSITIONSJanuary 2025September 2025Allow811NoNo
19030390AMINO ACID COMPOSITIONSJanuary 2025January 2026Allow1211YesNo
19030189AMINO ACID COMPOSITIONSJanuary 2025December 2025Allow1111YesNo
19030481MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTSJanuary 2025June 2025Abandon510NoNo
19003866COMPOSITIONS CONTAINING SHORT-CHAIN FATTY ACID, METHODS OF USE, AND METHODS OF MAKING THEREOFDecember 2024August 2025Allow710NoNo
19000003INDOXACARB SUSPENSION CONCENTRATE FORMULATIONSDecember 2024September 2025Allow910YesNo
18999331ACYLSULFONAMIDE KAT6A INHIBITORSDecember 2024April 2025Allow410YesNo
18977389METHODS OF TREATING GRADE 3 ASTROCYTOMADecember 2024January 2026Allow1330YesNo
18960975HERBICIDAL AND PESTICIDAL COMPOSITIONS AND METHODS OF USE THEREOFNovember 2024October 2025Abandon1111NoNo
18955937METHOD OF INHIBITING TAU PHOSPHORYLATIONNovember 2024February 2026Allow1520YesNo
18955938METHOD OF INHIBITING TAU PHOSPHORYLATIONNovember 2024February 2026Allow1510YesNo
18955261PHENETHYLAMINES AND CATHINONES PRECURSORSNovember 2024February 2025Allow300NoNo
18952842THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CHECKPOINT INHIBITOR-RESISTANT TUMORS USING PLINABULIN-BASED COMBINATION THERAPIESNovember 2024June 2025Allow611YesNo
18947694Liquid Tasimelteon Formulations and Methods of Use ThereofNovember 2024May 2025Allow610YesNo
18942141COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSNovember 2024September 2025Abandon1120NoNo
18932827PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEOctober 2024May 2025Allow620YesNo
18932033HYDROCORTISONE ORAL LIQUID FORMULATIONSOctober 2024June 2025Allow720YesNo
18926907METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENOctober 2024February 2025Allow310YesNo
18920162MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASEOctober 2024December 2025Allow1431NoNo
18920212SMALL MOLECULE INHIBITORS OF KRAS PROTEINSOctober 2024March 2025Allow501NoNo
18916471METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICSOctober 2024April 2025Allow610YesNo
18911778PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONEOctober 2024September 2025Abandon1220YesNo
18912328MIRDAMETINIB TREATMENTOctober 2024February 2026Abandon1620NoNo
18912341MIRDAMETINIB TREATMENTOctober 2024February 2026Abandon1620NoNo
18908278Oral Allopregnanolone Compositions and Methods of UseOctober 2024May 2025Allow710NoNo
18901359PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBSeptember 2024March 2025Allow510YesNo
18901530MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERSSeptember 2024May 2025Allow710YesNo
18897889ISOXAZOLINE PARASITICIDE FORMULATIONSSeptember 2024March 2025Allow610NoNo
188189262-(5-AMINOPYRIDIN-2-YL)-N-BENZYLACETAMIDES AND USE THEREOF IN THE TREATMENT OF ACUTE MYELOID LEUKEMIAAugust 2024March 2025Allow610NoNo
18794551PI3K INHIBITORSAugust 2024December 2024Allow501YesNo
18770514READY-TO-USE KETAMINE PREMIX FORMULATIONJuly 2024March 2025Allow821YesNo
18752072N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USINGJune 2024December 2024Allow511NoNo
18721770DRUG COMBINATION FOR TREATMENT OF GASTRIC CANCERJune 2024April 2025Allow1020NoNo
18745858AMINO ACID COMPOSITIONSJune 2024June 2025Allow1221NoNo
18743946(E)-1-(2-(4-SUBSTITUTEDPHENYL)-2-OXOETHYL)-4-((HYDROXYIMINO)METHYL)PYRIDINIUM BROMIDES AS ANTITUBERCULAR AGENTSJune 2024September 2024Allow300NoNo
18742438PHENOXY AND BENZYLOXY SUBSTITUTED PSYCHOPLASTOGENS AND USES THEREOFJune 2024September 2024Allow300NoNo
18740610METHODS RELATED TO OPIOID THERAPEUTICSJune 2024January 2025Allow700NoNo
18736166NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDSJune 2024September 2025Allow1510YesNo
18732301INHIBITORS OF TYK2June 2024March 2025Allow920YesNo
18677055Method Of Treatment Of ObesityMay 2024September 2025Allow1611NoNo
18675317LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONSMay 2024April 2025Allow1021YesNo
18676249NICORANDIL DERIVATIVESMay 2024June 2025Allow1310YesNo
18670588METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon910NoNo
18670580METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon910NoNo
18670555Base-Modified Cytidine Nucleotides for Leukemia TherapyMay 2024July 2025Allow1410NoNo
18670604METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024April 2025Abandon1110NoNo
18670556METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTSMay 2024May 2025Abandon1110NoNo
18670524METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTSMay 2024May 2025Abandon1110NoNo
18668653STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVEMay 2024June 2025Allow1310YesNo
18667748POLYMERIC BIOMATERIALS DERIVED FROM PHENOLIC MONOMERS AND THEIR MEDICAL USESMay 2024March 2026Allow2221NoNo
18665714LIQUID ORAL FORMULATIONS FOR TADALAFILMay 2024November 2024Allow610NoNo
18660698ANTICANCER COMPOSITIONSMay 2024April 2025Allow1120NoNo
186584601-(4-CARBONOIMIDOYLPHENOXY)-3-{4-[(E)-(PHENYLIMINO)METHYL]PHENOXY}PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)May 2024August 2024Allow400YesNo
18651454COMPOSITIONS CONTAINING SHORT-CHAIN FATTY ACID, METHODS OF USE, AND METHODS OF MAKING THEREOFApril 2024November 2024Allow720YesNo
18642074NOVEL THERAPYApril 2024July 2025Abandon1401NoNo
18642051In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid TumorsApril 2024May 2025Allow1310YesNo
18638787METHOD FOR CONTROLLING RUSTApril 2024July 2025Abandon1510NoNo
18636148METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASEApril 2024August 2024Allow410NoNo
18635779CONTROLLED RELEASE FORMULATION AND MINIMALLY INVASIVE METHOD OF ADMINISTRATIONApril 2024July 2024Allow310NoNo
18634899APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVEApril 2024October 2025Allow1810NoNo
18629507HUMAN THERAPEUTIC AGENTSApril 2024June 2025Abandon1410NoNo
18629703Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereofApril 2024September 2025Allow1800NoNo
18626876LIQUID ORAL FORMULATIONS FOR SILDENAFILApril 2024November 2024Allow710YesNo
18624045(2E)-4-[(4-CHLOROPHENYL)AMINO]-N-PHENYL-2-(PHENYLIMINO)-1,3,5-DIOXAZEPINE-7-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024June 2024Allow200NoNo
18696857VANIN-1 INHIBITORMarch 2024June 2024Allow200YesNo
18620393COMPOSITIONS CONTAINING PARAXANTHINE AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCEMarch 2024July 2024Allow300YesNo
18616625Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic VirusMarch 2024February 2026Abandon2240YesNo
18614911MACROCYCLIC COMPOUNDS AND METHODS OF USEMarch 2024July 2024Allow400YesNo
18606788Method and Composition for Treating Non-Cirrhotic NashMarch 2024January 2026Allow2241NoYes
18604704ISATIN DERIVATIVESMarch 2024April 2025Allow1410NoNo
18601088FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASEMarch 2024March 2026Allow2420NoNo
18601923NOVEL COMPOUNDS AND METHODSMarch 2024October 2025Allow1910YesNo
18600301TREATING SAR-COV-2 RELATED HEALTH PROBLEMSMarch 2024May 2025Abandon1410NoNo
18595919USE OF THYROID BETA-AGONISTSMarch 2024July 2025Allow1611NoNo
18595742STABLE SALT AND CRYSTAL FORMS OF 2-[3-({1-[2-(DIMETHYLAMINO)ETHYL]-2-(2,2-DIMETHYLPROPYL)-1H-1,3-BENZODIAZOL-5-YL}SULFONYL)AZETIDIN-1-YL]ETHAN-1-OLMarch 2024January 2026Allow2310NoNo
18590435BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTIONFebruary 2024May 2025Abandon1420YesNo
18590806COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONSFebruary 2024September 2024Allow711YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1627.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
437
Examiner Affirmed
311
(71.2%)
Examiner Reversed
126
(28.8%)
Reversal Percentile
30.9%
Lower than average

What This Means

With a 28.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1990
Allowed After Appeal Filing
383
(19.2%)
Not Allowed After Appeal Filing
1607
(80.8%)
Filing Benefit Percentile
5.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1627 - Prosecution Statistics Summary

Executive Summary

Art Unit 1627 is part of Group 1620 in Technology Center 1600. This art unit has examined 15,057 patent applications in our dataset, with an overall allowance rate of 46.7%. Applications typically reach final disposition in approximately 33 months.

Comparative Analysis

Art Unit 1627's allowance rate of 46.7% places it in the 6% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1627 receive an average of 2.05 office actions before reaching final disposition (in the 63% percentile). The median prosecution time is 33 months (in the 35% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.